Savara (SVRA) Competitors $2.13 +0.04 (+1.67%) Closing price 03:58 PM EasternExtended Trading$2.19 +0.06 (+2.81%) As of 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. EVO, OCUL, GRDN, AUPH, HROW, DYN, ELVN, VERV, COLL, and AKBAShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Evotec (EVO), Ocular Therapeutix (OCUL), Guardian Pharmacy Services (GRDN), Aurinia Pharmaceuticals (AUPH), Harrow (HROW), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "med - drugs" industry. Savara vs. Its Competitors Evotec Ocular Therapeutix Guardian Pharmacy Services Aurinia Pharmaceuticals Harrow Dyne Therapeutics Enliven Therapeutics Verve Therapeutics Collegium Pharmaceutical Akebia Therapeutics Savara (NASDAQ:SVRA) and Evotec (NASDAQ:EVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership. Which has preferable valuation and earnings, SVRA or EVO? Savara has higher earnings, but lower revenue than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSavaraN/AN/A-$95.88M-$0.48-4.45Evotec$862.40M1.73-$212.18MN/AN/A Is SVRA or EVO more profitable? Savara has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets SavaraN/A -65.88% -52.35% Evotec -26.34%-21.51%-10.54% Which has more risk & volatility, SVRA or EVO? Savara has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, Evotec has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Do analysts rate SVRA or EVO? Savara currently has a consensus target price of $5.60, indicating a potential upside of 162.30%. Evotec has a consensus target price of $5.93, indicating a potential upside of 41.44%. Given Savara's stronger consensus rating and higher possible upside, equities research analysts clearly believe Savara is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Savara 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Do insiders and institutionals believe in SVRA or EVO? 87.9% of Savara shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 5.3% of Savara shares are owned by company insiders. Comparatively, 1.0% of Evotec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media favor SVRA or EVO? In the previous week, Savara had 1 more articles in the media than Evotec. MarketBeat recorded 3 mentions for Savara and 2 mentions for Evotec. Evotec's average media sentiment score of 1.16 beat Savara's score of 0.00 indicating that Evotec is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySavara beats Evotec on 8 of the 13 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$362.96M$2.44B$5.54B$8.95BDividend YieldN/A1.77%5.38%4.08%P/E Ratio-4.458.8627.3820.03Price / SalesN/A680.43422.31120.16Price / CashN/A157.0736.6357.47Price / Book2.144.638.085.67Net Income-$95.88M$31.34M$3.16B$248.47M7 Day Performance-3.39%0.84%2.12%2.90%1 Month Performance-11.04%7.92%4.43%5.75%1 Year Performance-50.69%1.87%35.62%21.36% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara1.828 of 5 stars$2.14+1.7%$5.60+162.3%-51.2%$362.96MN/A-4.45N/AGap UpEVOEvotec1.7251 of 5 stars$4.20+1.0%$5.93+41.3%-12.3%$1.48B$862.40M0.004,827Positive NewsOCULOcular Therapeutix3.7997 of 5 stars$9.28+0.7%$17.33+86.8%+41.6%$1.47B$63.72M0.00230Gap UpGRDNGuardian Pharmacy Services1.4407 of 5 stars$21.39+0.0%$25.67+20.0%N/A$1.35B$1.23B0.003,400High Trading VolumeAUPHAurinia Pharmaceuticals3.1052 of 5 stars$8.47-2.0%$11.50+35.8%+37.9%$1.17B$235.13M23.35300News CoverageHROWHarrow2.7246 of 5 stars$30.54-1.1%$61.40+101.0%+46.6%$1.13B$199.61M0.00182Positive NewsDYNDyne Therapeutics3.5061 of 5 stars$9.52-0.5%$41.13+332.0%-74.2%$1.09BN/A0.00100ELVNEnliven Therapeutics2.5229 of 5 stars$20.06-3.0%$39.60+97.4%-4.9%$1.01BN/A0.0050Analyst ForecastVERVVerve Therapeutics3.3086 of 5 stars$11.23-0.6%$14.57+29.8%+124.2%$1.01B$32.33M0.00110COLLCollegium Pharmaceutical4.0288 of 5 stars$29.57-1.2%$43.75+48.0%-4.8%$961.71M$631.45M5.19210AKBAAkebia Therapeutics4.3589 of 5 stars$3.64-0.3%$6.75+85.4%+278.1%$958.62M$160.18M0.00430Insider Trade Related Companies and Tools Related Companies EVO Alternatives OCUL Alternatives GRDN Alternatives AUPH Alternatives HROW Alternatives DYN Alternatives ELVN Alternatives VERV Alternatives COLL Alternatives AKBA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SVRA Stock Alerts